Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30396411 | 1.00 | ACLY (0.37) | ACLYKDM4EMEN1MAPTKMT2A | |
| SCHEMBL20536246 | 0.84 | SMN1; SMN2 (0.37) | ALDH1A1HDAC1HDAC8LMNASMN1; SMN2 | |
| SCHEMBL20536245 | 0.84 | SMN1; SMN2 (0.37) | ALDH1A1HDAC1HDAC8LMNASMN1; SMN2 | |
| SCHEMBL29015479 | 0.84 | SMN1; SMN2 (0.37) | ALDH1A1HDAC1HDAC8LMNASMN1; SMN2 | |
| SCHEMBL19343560 | 0.84 | MAPT (0.40) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL26372679 | 0.83 | GABRA1 (0.42) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL20535850 | 0.82 | MAPT (0.35) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL19343270 | 0.82 | SCD (0.38) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL20535851 | 0.82 | MAPT (0.35) | KDM4EMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL24113139 | 0.82 | CA1 (0.39) | MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | ACLY 3152/4885KDM4E 3205/4885MEN1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.